The FDA has expanded the approved uses of Kalydeco (ivacaftor), which is used to treat cystic fibrosis, so it can now be used by patients with any of 33 rare gene mutations.
The FDA has expanded the approved uses of Kalydeco (ivacaftor), which is used to treat cystic fibrosis, so it can now be used by patients with any of 33 rare gene mutations.
When Kalydeco was first approved in 2012, it was indicated for the treatment of 10 mutations that cause cystic fibrosis. The rare disease is caused by a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which regulates the movement of ions and water in and out of cells. The mutation causes secretions to accumulate in the lungs and digestive tract, resulting in severe respiratory and digestive problems and potentially contributing to complications like diabetes or infections.
About 30,000 Americans are living with cystic fibrosis, and the expanded indication to 23 additional types of gene mutations means that 900 more people in the United States can use Kalydeco to treat their cystic fibrosis. For years, the small pool of patients with the disease made it difficult to determine which indications were appropriate for the drug, according to Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research.
“Many rare cystic fibrosis mutations have such small patient populations that clinical trial studies are not feasible,” Woodcock said in the press release announcing the expanded approval. “This challenge led us to using an alternative approach based on precision medicine, which made it possible to identify certain gene mutations that are likely to respond to Kalydeco.”
Laboratory researchers used in vitro cells to assess which mutations responded to Kalydeco, which serves as a predictor of response to treatment. Regulators then could extend the clinical results seen in the drug’s prior clinical trials, where it successfully treated patients with the other gene mutations, to the mutations that had responded in the laboratory.
Kalydeco works by improving the functioning of the proteins manufactured by the CTFR gene, which helps it better regulate the movement of fluids between cells and reduces the respiratory symptoms. Patients can undergo a mutation test to determine if their particular gene mutation is one that will respond to Kalydeco.
According to a press release from Vertex, the manufacturer of Kalydeco, the expanded approval is a significant step towards increasing access to treatment for those living with cystic fibrosis.
“We are encouraged by the FDA's willingness to explore innovative ways to make highly effective medicines like Kalydeco with a well-established safety profile available to more people who are in urgent need,” said Jeffery Chodakewitz, MD, executive vice president and chief medical officer. “We will continue to work closely with the FDA to bring Kalydeco to more people with responsive mutations who are still in need as rapidly as possible."
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More